INmune Bio
INMB
INMB
33 hedge funds and large institutions have $19.1M invested in INmune Bio in 2022 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 10 increasing their positions, 9 reducing their positions, and 10 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
less ownership
Funds ownership: →
less call options, than puts
Call options by funds: $ | Put options by funds: $
less funds holding
Funds holding: →
24% less capital invested
Capital invested by funds: $25.3M → $19.1M (-$6.17M)
90% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 10
Holders
33
Holding in Top 10
–
Calls
$300K
Puts
$356K
Top Buyers
| 1 | +$1.24M | |
| 2 | +$359K | |
| 3 | +$175K | |
| 4 |
Marshall Wace
London,
United Kingdom
|
+$84.2K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$77.9K |
Top Sellers
| 1 | -$1.54M | |
| 2 | -$657K | |
| 3 | -$349K | |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$324K |
| 5 |
VF
Virtu Financial
New York
|
-$249K |